Studies of Hereditary Neurological Disease: Disease Mechanisms
遗传性神经系统疾病的研究:疾病机制
基本信息
- 批准号:8557057
- 负责人:
- 金额:$ 148.71万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:AcuteAddressAllelesAmino Acyl-tRNA SynthetasesAndrogen ReceptorAnimal ModelAttenuatedBinding ProteinsBioavailableBlindedBody Weight decreasedCaenorhabditis elegansCell Culture TechniquesCharcot-Marie-Tooth DiseaseClinicalClinical TrialsCultured CellsDenervationDiseaseDisease ProgressionDoseGenesGeneticGenetic Complementation TestGlutamineGlycine-tRNA LigaseGoalsHeterozygoteHistone Deacetylase InhibitorHistone deacetylase inhibitionHistonesHomozygoteHumanIGF1 geneIn VitroInheritedInjection of therapeutic agentInsulin-Like Growth Factor IInterventionIntraperitoneal InjectionsInvestigationKennedy SyndromeLinkMediatingMindMissense MutationModelingMotorMotor Neuron DiseaseMusMuscleMuscle ProteinsMuscular AtrophyMutant Strains MiceMutationMyogeninMyopathyNeurologicNeuromuscular DiseasesNeuromuscular JunctionNeuropathyOnset of illnessOrthologous GenePathologyPathway interactionsPatientsPerformancePeripheralPeripheral Nervous System DiseasesPhenotypePhosphorylationPoint MutationProteasome InhibitionProtein DeficiencyProtein IsoformsProteinsRandomizedReceptor AggregationRecombinant IGF-IRecombinantsResearchRing Finger DomainSpinal CordSpinal Muscular AtrophySystemTestingTherapeutic InterventionTissuesToxic effectTransgenesTransgenic MiceTransgenic OrganismsUbiquitinbehavior testdosageeffective therapygain of functionglycine-tRNAhereditary neuropathyhuman HDAC4 proteinimprovedknock-downloss of functionmouse modelmulticatalytic endopeptidase complexmutantnervous system disorderneuromuscular functionnew therapeutic targetoverexpressionpolyglutamineprogramsprotein degradationspinal and bulbar muscular atrophytherapeutic targetubiquitin-protein ligase
项目摘要
The purpose of this research program is to investigate the mechanisms of hereditary neurological diseases, with the ultimate intent of developing effective treatments for these disorders. Recently, the research has focused on two specific neuromuscular diseases: autosomal recessive spinal muscular atrophy (SMA) due to deficiency of the protein SMN, X-linked spinal and bulbar muscular atrophy (SBMA) due to polyglutamine expansion in the androgen receptor. Specific research accomplishments in the past year include the following:
(1) Identification of an E3 ligase, mind bomb 1 (Mib1), responsible for the degradation of SMN protein. SMN is ubiquitinated and degraded through the ubiquitin proteasome system (UPS). We have previously shown that proteasome inhibition improves motor function, and reduces spinal cord, muscle, and neuromuscular junction pathology of spinal muscular atrophy mice, suggesting that the UPS is a potential therapeutic target for this disease. While inhibiting the proteasome provides proof of concept that the UPS can be targeted to increase SMN protein levels, specific targets in this pathway may be more efficacious and less toxic. In this study, we show that the E3 ubiquitin ligase, Mib1, interacts with and ubiquitinates SMN and facilitates its degradation. Knocking down Mib1 levels increases SMN protein levels in cultured cells. In addition, knocking down the Mib1 ortholog improves neuromuscular function in Caenorhabditis elegans deficient in SMN. These findings demonstrate that Mib1 ubiquitinates and catalyzes the degradation of SMN, and thus represents a novel therapeutic target for spinal muscular atrophy.
(2) Characterization of the effects of histone deacetylase inhibition in SMA muscle. During muscle atrophy, the E3 ligase atrogenes, atrogin-1 and muscle ring finger 1 (MuRF1), mediate muscle protein breakdown through the ubiquitin proteasome system. Atrogene expression can be induced by various upstream regulators. During acute denervation, they are activated by myogenin, which is in turn regulated by histone deacetylases 4 and 5. We showed that atrogenes are induced in SMA model mice and in SMA patient muscle in association with increased myogenin and histone deacetylase-4 (HDAC4) expression. This activation during both acute denervation and SMA disease progression is suppressed by treatment with a histone deacetylase inhibitor; however, this treatment has no effect when atrogene induction occurs independently of myogenin. These results indicate that myogenin-dependent atrogene induction is amenable to pharmacological intervention with histone deacetylase inhibitors and help to explain the beneficial effects of these agents on SMA and other denervating diseases.
(3) Characterization of the effects of IGF-1 in an animal model of SBMA. Our recent studies have demonstrated that IGF-1 reduces the mutant androgen receptor toxicity through activation of Akt in vitro, and spinal and bulbar muscular atrophy transgenic mice that also overexpress a non-circulating muscle isoform of IGF-1 have a less severe phenotype. Here we sought to establish the efficacy of daily intraperitoneal injections of mecasermin rinfabate, recombinant human IGF-1 and IGF-1 binding protein 3, in a transgenic mouse model expressing the mutant androgen receptor with an expanded 97 glutamine tract. The study was done in a controlled, randomized, blinded fashion, and in order to reflect the clinical settings the injections were started after the onset of disease manifestations. The treatment resulted in increased Akt phosphorylation and reduced mutant androgen receptor aggregation in muscle. In comparison to vehicle-treated controls, IGF-1 treated transgenic mice showed improved motor performance, attenuated weight loss, and increased survival. Our results suggest that peripheral tissue can be targeted to improve the spinal and bulbar muscular atrophy phenotype and indicate that IGF-1 warrants further investigation in clinical trials as a potential treatment for this disease.
(4) Characterization of the mechanism of hereditary neuropathy due to mutation in glycine tRNA synthtase (GARS). Charcot-Marie-Tooth disease type 2D (CMT2D) is a dominantly inherited peripheral neuropathy caused by missense mutations in the glycyl-tRNA synthetase gene (GARS). In addition to GARS, mutations in three other tRNA synthetase genes cause similar neuropathies, although the underlying mechanisms are not fully understood. To address this, we generated transgenic mice that ubiquitously over-express wild-type GARS and crossed them to two dominant mouse models of CMT2D to distinguish loss-of-function and gain-of-function mechanisms. Over-expression of wild-type GARS does not improve the neuropathy phenotype in heterozygous Gars mutant mice, as determined by histological, functional, and behavioral tests. Transgenic GARS is able to rescue a pathological point mutation as a homozygote or in complementation tests with a Gars null allele, demonstrating the functionality of the transgene and revealing a recessive loss-of-function component of the point mutation. Missense mutations as transgene-rescued homozygotes or compound heterozygotes have a more severe neuropathy than heterozygotes, indicating that increased dosage of the disease-causing alleles results in a more severe neurological phenotype, even in the presence of a wild-type transgene. We conclude that, although missense mutations of Gars may cause some loss of function, the dominant neuropathy phenotype observed in mice is caused by a dose-dependent gain of function that is not mitigated by over-expression of functional wild-type protein.
该研究计划的目的是调查遗传性神经系统疾病的机制,最终目的是为这些疾病开发有效的治疗方法。最近,研究集中在两种特定的神经肌肉疾病:由于蛋白SMN缺乏引起的常染色体隐性脊髓性肌萎缩症(SMA),由于雄激素受体中的聚谷氨酰胺扩增引起的X连锁脊髓和延髓肌萎缩症(SBMA)。过去一年的具体研究成果包括:
(1)鉴定负责SMN蛋白降解的E3连接酶,mind bomb 1(Mib 1)。SMN通过泛素蛋白酶体系统(UPS)被泛素化和降解。我们以前已经表明,蛋白酶体抑制改善运动功能,并减少脊髓性肌萎缩症小鼠的脊髓,肌肉和神经肌肉接头病理,这表明UPS是这种疾病的潜在治疗靶点。虽然抑制蛋白酶体提供了UPS可以靶向增加SMN蛋白水平的概念证据,但该途径中的特定靶标可能更有效且毒性更低。在这项研究中,我们表明,E3泛素连接酶,Mib 1,与SMN相互作用,并泛素化,促进其降解。敲低Mib 1水平会增加培养细胞中的SMN蛋白水平。此外,敲低Mib 1直系同源物改善了SMN缺陷的秀丽隐杆线虫的神经肌肉功能。这些发现表明Mib 1泛素化并催化SMN的降解,因此代表了脊髓性肌萎缩症的新治疗靶点。
(2)SMA肌肉中组蛋白脱乙酰酶抑制作用的表征。在肌肉萎缩期间,E3连接酶atrogenes、atrogin-1和肌肉环指1(MuRF 1)通过泛素蛋白酶体系统介导肌肉蛋白质分解。Atrogene的表达可由多种上游调节因子诱导。在急性失神经支配期间,它们被肌细胞生成素激活,而肌细胞生成素又被组蛋白脱乙酰酶4和5调节。我们发现,在SMA模型小鼠和SMA患者肌肉中,与肌细胞生成素和组蛋白脱乙酰酶-4(HDAC 4)表达增加相关的萎缩基因被诱导。急性去神经支配和SMA疾病进展期间的这种激活通过组蛋白去乙酰化酶抑制剂治疗受到抑制;然而,当atrogen诱导独立于肌细胞生成素发生时,这种治疗没有效果。这些结果表明,肌细胞生成素依赖性萎缩基因诱导是服从组蛋白去乙酰化酶抑制剂的药理学干预,并有助于解释这些药物对SMA和其他去神经疾病的有益作用。
(3)SBMA动物模型中IGF-1作用的表征。我们最近的研究表明,IGF-1通过激活Akt在体外降低突变雄激素受体的毒性,脊髓和延髓肌肉萎缩症的转基因小鼠,也过表达IGF-1的非循环肌肉亚型有一个不太严重的表型。在此,我们试图在表达突变型雄激素受体的转基因小鼠模型中建立每日腹膜内注射mecasermin rinfabate(重组人IGF-1和IGF-1结合蛋白3)的疗效,该突变型雄激素受体具有扩展的97谷氨酰胺通道。本研究以对照、随机、设盲的方式进行,并且为了反映临床环境,在疾病表现发作后开始注射。治疗导致Akt磷酸化增加和肌肉中突变雄激素受体聚集减少。与溶剂处理的对照组相比,IGF-1处理的转基因小鼠表现出运动能力改善、体重减轻减轻和生存率提高。我们的研究结果表明,外周组织可以有针对性地改善脊髓和延髓肌萎缩表型,并表明IGF-1值得进一步研究,在临床试验中作为一种潜在的治疗这种疾病。
(4)甘氨酸tRNA还原酶(加尔斯)突变引起遗传性神经病的机制表征。腓骨肌萎缩症2D型(CMT 2D)是由甘氨酰-tRNA合成酶基因(加尔斯)错义突变引起的显性遗传性周围神经病变。除了加尔斯,其他三种tRNA合成酶基因的突变也会导致类似的神经病变,尽管其潜在机制尚未完全了解。为了解决这个问题,我们产生了普遍过表达野生型加尔斯的转基因小鼠,并将它们与两种CMT 2D显性小鼠模型杂交,以区分功能丧失和功能获得机制。野生型加尔斯的过度表达并不能改善杂合型加尔斯突变小鼠的神经病变表型,这是通过组织学、功能和行为测试确定的。转基因加尔斯能够作为纯合子或在与加尔斯无效等位基因的互补试验中挽救病理性点突变,证明了转基因的功能性并揭示了点突变的隐性功能丧失组分。错义突变作为转基因挽救的纯合子或复合杂合子具有比杂合子更严重的神经病变,表明即使在野生型转基因存在下,致病等位基因的剂量增加也会导致更严重的神经学表型。我们的结论是,虽然错义突变的加尔斯可能会导致一些功能丧失,在小鼠中观察到的显性神经病变表型是由剂量依赖性增益的功能,不减轻过度表达的功能野生型蛋白。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kenneth Fischbeck其他文献
Kenneth Fischbeck的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kenneth Fischbeck', 18)}}的其他基金
Studies Of Hereditary Neurological Disease: Disease Gene Identification
遗传性神经疾病的研究:疾病基因鉴定
- 批准号:
9563109 - 财政年份:
- 资助金额:
$ 148.71万 - 项目类别:
Studies Of Hereditary Neurological Disease: Clinical Trials
遗传性神经系统疾病的研究:临床试验
- 批准号:
8342258 - 财政年份:
- 资助金额:
$ 148.71万 - 项目类别:
Studies Of Hereditary Neurological Disease: Clinical Trials
遗传性神经系统疾病的研究:临床试验
- 批准号:
7594728 - 财政年份:
- 资助金额:
$ 148.71万 - 项目类别:
Studies Of Hereditary Neurological Disease: Disease Gene Identification
遗传性神经疾病的研究:疾病基因鉴定
- 批准号:
10708600 - 财政年份:
- 资助金额:
$ 148.71万 - 项目类别:
Studies of Hereditary Neurological Disease: Disease Mechanisms
遗传性神经系统疾病的研究:疾病机制
- 批准号:
10708607 - 财政年份:
- 资助金额:
$ 148.71万 - 项目类别:
Studies of Hereditary Neurological Disease: Disease Mechanisms
遗传性神经系统疾病的研究:疾病机制
- 批准号:
8342259 - 财政年份:
- 资助金额:
$ 148.71万 - 项目类别:
Studies Of Hereditary Neurological Disease: Clinical Trials
遗传性神经系统疾病的研究:临床试验
- 批准号:
8746816 - 财政年份:
- 资助金额:
$ 148.71万 - 项目类别:
Studies of Hereditary Neurological Disease: Disease Mechanisms
遗传性神经系统疾病的研究:疾病机制
- 批准号:
8746817 - 财政年份:
- 资助金额:
$ 148.71万 - 项目类别:
Studies Of Hereditary Neurological Disease: Disease Gene Identification
遗传性神经疾病的研究:疾病基因鉴定
- 批准号:
7969580 - 财政年份:
- 资助金额:
$ 148.71万 - 项目类别:
Studies Of Hereditary Neurological Disease: Clinical Trials
遗传性神经系统疾病的研究:临床试验
- 批准号:
10932761 - 财政年份:
- 资助金额:
$ 148.71万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 148.71万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 148.71万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 148.71万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 148.71万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 148.71万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 148.71万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 148.71万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 148.71万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 148.71万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 148.71万 - 项目类别:
Research Grant